iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma

Affiliations

¹ Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
² Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: rizwan_romee@dfci.harvard.edu.

Comment

Roman M Shapiro et al. Lancet. 2025.

. 2025 Jan 11;405(10473):98-99.

doi: 10.1016/S0140-6736(24)02524-8.

¹ Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
² Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: rizwan_romee@dfci.harvard.edu.

No abstract available

Comment on

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.
Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, Bachier C, Diefenbach CS, Wong C, Bickers C, Wong L, Patel D, Goodridge J, Denholt M, Valamehr B, Elstrom RL, Strati P. Ghobadi A, et al. Lancet. 2025 Jan 11;405(10473):127-136. doi: 10.1016/S0140-6736(24)02462-0. Lancet. 2025. PMID: 39798981 Clinical Trial.